文献速递心律失常

ENGAGE AF-TIMI 48试验:亚洲房颤患者与未服抗凝药非亚洲患者的临床结局、依多沙班浓度及抗Xa活性比较

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
PubMed 文献 · Eur Heart J · 2019-01-01

亚洲患者华法林相关颅内出血风险更高(aHR 1.71,P=0.03),但缺血性卒中风险无显著差异。亚洲患者依多沙班谷浓度和抗Xa活性低20-25%,高剂量依多沙班在亚洲和非亚洲患者中均显著降低颅内出血且保持卒中预防疗效。

要点

  • 亚洲房颤患者华法林治疗颅内出血风险较非亚洲患者高71%(aHR 1.71,P=0.03)。
  • 亚洲患者依多沙班谷浓度及抗Xa活性较非亚洲患者低20-25%。
  • 高剂量依多沙班在亚洲和非亚洲患者中均显著降低颅内出血且保持卒中预防疗效。

核心结论

  • 与华法林相比,高剂量依多沙班在亚洲患者中保持卒中预防疗效并具有有利的安全性特征,可能归因于亚洲患者达到较低的依多沙班谷浓度和抗Xa活性。

主要发现

  • 华法林组中,亚洲与非亚洲患者调整后缺血性卒中风险无显著差异(aHR=1.12,P=0.56)。
  • 华法林治疗的亚洲患者较非亚洲患者调整后颅内出血风险更高(aHR 1.71,P=0.03)。
  • 亚洲患者依多沙班谷浓度和抗Xa活性较非亚洲患者低20-25%。
  • 与华法林相比,高剂量依多沙班在亚洲和非亚洲患者中均显著降低颅内出血,同时保持卒中预防疗效。
  • 三项净临床结局中有两项在亚洲患者中依多沙班较华法林更有利(交互P值分别为0.063、0.037和0.032)。

关键数值与推荐

  • 华法林组亚洲与非亚洲患者调整后缺血性卒中风险aHR=1.12(P=0.56)。
  • 华法林组亚洲患者较非亚洲患者调整后颅内出血风险aHR=1.71(P=0.03)。
  • 亚洲患者依多沙班谷浓度和抗Xa活性较非亚洲患者低20-25%。
  • 三项净临床结局交互P值分别为0.063、0.037和0.032。

临床怎么用

  • 对于亚洲房颤患者,高剂量依多沙班可考虑作为华法林的替代选择,以降低颅内出血风险并维持卒中预防疗效。
  • 亚洲患者使用依多沙班时可能因较低的谷浓度和抗Xa活性而具有更有利的安全性特征,但需注意个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Prior studies suggested that the risks of ischaemic stroke and bleeding in patients of Asian race with atrial fibrillation (AF) may be higher than that of non-Asians. In the analysis of ENGAGE AF-TIMI 48 trial, we compared clinical outcomes, edoxaban concentration, and anti-factor Xa (anti-FXa) activity, between Asian and non-Asian races. METHODS AND RESULTS: There were 2909 patients of Asian race and 18 195 non-Asian race in the ENGAGE AF-TIMI 48 trial. The risks of thromboembolism and bleeding events were compared for Asians and non-Asians treated with warfarin. The trough levels of edoxaban concentration and anti-FXa activity were also compared and correlated with the efficacy and safety of edoxaban vs. warfarin. Compared to non-Asian patients, the Asian population was on average 2 years younger and 20 kg lighter. In the warfarin group, the adjusted risk of ischaemic stroke did not differ significantly for patients of Asian and non-Asian race [adjusted hazard ratio (aHR) = 1.12, P = 0.56). Asians treated with warfarin had a higher-adjusted risk of intracranial haemorrhage (ICH: aHR 1.71, P = 0.03) compared with non-Asians. The trough edoxaban concentration and anti-FXa activity were 20-25% lower for Asians compared with non-Asians. Compared to warfarin, higher dose edoxaban significantly reduced ICH while preserving the efficacy of stroke prevention in both Asians and non-Asians. Two of three net clinical outcomes appeared to be more favourably reduced with edoxaban in Asians compared with non-Asians (Pint = 0.063 for primary, 0.037 for secondary, and 0.032 for third net clinical outcomes, respectively). CONCLUSION: Compared to warfarin, higher dose edoxaban preserved the efficacy for stroke prevention and was associated with a favourable safety profile for Asians, which may be due to the lower trough edoxaban concentration and anti-FXa activity achieved in patients of Asian race.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chao TF, Chen SA, Ruff CT, et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019. PMID: 30590425. doi:10.1093/eurheartj/ehy807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。